Kintegral Advisory LLC Has $3.80 Million Stock Position in Boston Scientific Corporation (NYSE:BSX)

Kintegral Advisory LLC trimmed its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 32.9% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 37,622 shares of the medical equipment provider's stock after selling 18,451 shares during the quarter. Kintegral Advisory LLC's holdings in Boston Scientific were worth $3,795,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds also recently bought and sold shares of BSX. Colonial Trust Co SC lifted its stake in Boston Scientific by 1,625.0% during the fourth quarter. Colonial Trust Co SC now owns 276 shares of the medical equipment provider's stock valued at $25,000 after buying an additional 260 shares in the last quarter. Investment Management Corp VA ADV purchased a new stake in Boston Scientific during the fourth quarter valued at about $25,000. Sunbeam Capital Management LLC purchased a new stake in Boston Scientific during the fourth quarter valued at about $26,000. Ameriflex Group Inc. purchased a new stake in Boston Scientific during the fourth quarter valued at about $31,000. Finally, Fairway Wealth LLC purchased a new stake in Boston Scientific during the fourth quarter valued at about $36,000. 89.07% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at Boston Scientific

In other Boston Scientific news, CEO Michael F. Mahoney sold 164,443 shares of the stock in a transaction that occurred on Monday, June 2nd. The stock was sold at an average price of $103.69, for a total transaction of $17,051,094.67. Following the transaction, the chief executive officer owned 1,476,882 shares in the company, valued at $153,137,894.58. This trade represents a 10.02% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP John Bradley Sorenson sold 4,572 shares of the stock in a transaction that occurred on Monday, May 5th. The shares were sold at an average price of $104.54, for a total value of $477,956.88. Following the transaction, the executive vice president owned 18,705 shares in the company, valued at approximately $1,955,420.70. This trade represents a 19.64% decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 461,970 shares of company stock valued at $47,755,193. 0.50% of the stock is owned by company insiders.

Boston Scientific Stock Up 0.6%

NYSE:BSX traded up $0.67 during mid-day trading on Friday, reaching $104.30. The stock had a trading volume of 2,931,148 shares, compared to its average volume of 6,666,246. The business's 50 day moving average is $103.42 and its 200 day moving average is $100.14. Boston Scientific Corporation has a fifty-two week low of $71.88 and a fifty-two week high of $107.53. The stock has a market cap of $154.30 billion, a P/E ratio of 76.13, a PEG ratio of 2.71 and a beta of 0.68. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.45 and a quick ratio of 0.88.

Boston Scientific (NYSE:BSX - Get Free Report) last released its quarterly earnings data on Wednesday, April 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.67 by $0.08. Boston Scientific had a return on equity of 18.67% and a net margin of 11.58%. The firm had revenue of $4.66 billion for the quarter, compared to the consensus estimate of $4.57 billion. During the same quarter in the prior year, the company posted $0.56 earnings per share. The firm's revenue was up 20.9% on a year-over-year basis. As a group, sell-side analysts predict that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Wall Street Analysts Forecast Growth

BSX has been the subject of a number of analyst reports. Barclays upped their price objective on shares of Boston Scientific from $118.00 to $125.00 and gave the company an "overweight" rating in a research note on Friday, April 25th. Leerink Partnrs raised shares of Boston Scientific to a "strong-buy" rating in a research note on Monday, June 16th. Erste Group Bank upgraded Boston Scientific to a "strong-buy" rating in a report on Thursday, May 8th. Royal Bank Of Canada upped their target price on Boston Scientific from $116.00 to $120.00 and gave the company an "outperform" rating in a report on Thursday, April 24th. Finally, Citigroup reiterated a "buy" rating and issued a $125.00 target price (up previously from $119.00) on shares of Boston Scientific in a report on Thursday, May 22nd. Twenty-two equities research analysts have rated the stock with a buy rating and three have given a strong buy rating to the company's stock. Based on data from MarketBeat.com, Boston Scientific presently has a consensus rating of "Buy" and a consensus price target of $116.09.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.